ATAI Life Sciences NV (NAS:ATAI)
$ 1.67 -0.01 (-0.6%) Market Cap: 279.57 Mil Enterprise Value: 195.80 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 26/100

ATAI Life Sciences NV at Citi BioPharma Conference Transcript

Sep 07, 2022 / 02:30PM GMT
Release Date Price: $4.29 (+1.90%)
Neena Marie Bitritto;Garg
Citigroup Inc., Research Division - VP & Analyst

I'm Neena Bitritto-Garg, and I'm one of the biotech analysts here at Citi. I'm very pleased to be joined for our next company panel where we're going to be focusing on mental health and new kind of innovative options for mental health conditions. I've got with me the new CEO of COMPASS Pathways, Kabir Nath; the Chief Medical Officer of Pear Therapeutics, Yuri Maricich; and Florian Brand, the CEO of Atai Life Sciences.

So before we get into Q&A, I want to pass it to each of you to make some opening remarks. And maybe we'll start with Florian.

Florian Brand
Atai Life Sciences N.V. - Co-founder & CEO

Sure, yes. Happy to be here. Thanks for overseeing us. And I think it's a very interesting panel as it combines a range of modalities that we, I think, all are working on, especially with the digital component. And so here is Atai, our biotech -- or biopharmaceutical company in the clinical stage and also heavily believe in the potential of digital

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot